Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis
François Prince(Hôpital du Sacré-Cœur de Montréal), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), R. ten Cate(Leiden University), Y. Koopman-Keemink(Juliana Kinderziekenhuis), Hein Raat(Erasmus MC), Esther P A H Hoppenreijs(Radboud University Nijmegen), Lianne M. Geerdink(Erasmus MC - Sophia Children’s Hospital), G. J. J. M. Borsboom(Erasmus MC), Marion A. J. van Rossum(Reade), M van Santen-Hoeufft(Maastricht University Medical Centre), Marinka Twilt(University of Calgary)
Cited by 64
Related Papers
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative
|Health and Quality of Life Outcomes|2013|168
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based survey
|Arthritis Care & Research|2012|155